Becker's Healthcare November 23, 2022
The FDA approved a hemophilia B drug with a list price of $3.5 million — which could save the healthcare system millions per patient according to drug maker CSL Behring.
Hemgenix is the first and only onetime gene therapy treatment for adults with hemophilia B who “currently use factor IX prophylaxis therapy, or have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes,” according to a Nov. 22 CSL release.
The drug reduces the rate of annual bleeds, reduces or eliminates the need for prophylactic therapy...
Today's Sponsors
Today's Sponsor